New drug combo aims to make bone marrow transplants safer for rare blood cancer

NCT ID NCT07104799

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests the safety and best dose of the drug momelotinib when given before, during, and after a stem cell transplant for people with myelofibrosis, a serious bone marrow disorder. About 28 participants will receive momelotinib pills daily for up to 13 cycles. The goal is to find a dose that limits side effects while supporting transplant recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Momelotinib (a drug taken orally once daily)
What this could lead to: If successful, this could point toward a safer way to use momelotinib alongside stem cell transplants for myelofibrosis, potentially improving outcomes.
What could go wrong: This is a very early (Phase 1) and small (28 people) trial focused on safety and dosing, not yet on effectiveness. It may not lead to a new standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC CELL TRANSPLANTATION (HCT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC CELL TRANSPLANTATION (HCT) MYELOFIBROSIS

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.